Decision: Favourable

Decisions Table

Study Title:

A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

  • NREC Code:

    22-NREC-CT-062

  • Decision:

    Favourable

  • Meeting Date:

    23/03/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Jarushka Naidoo

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Mirati Therapeutics, Inc.

Scroll to Top